Refining HEPAmet for Treatment Eligibility in Metabolic Dysfunction-Associated Steatotic Liver Disease: External Validation and Guardrail to Exclude Cirrhosis, Limit Early Disease
Related Experiment Video
Updated: Apr 15, 2026

09:02
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
12.5K
Tsubasa Tsutsumil1, Takumi Kawaguchi2, Hideki Fujii3
1Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Abstract
No abstract available in PubMed .

